Regulatory Pathway & Device Classification

The route by which a device becomes legally marketable, determined primarily by its risk classification. In the U.S., implanted BCIs are high-risk Class III devices that generally require Premarket Approval (PMA), the most stringent pathway, supported by valid scientific evidence of safety and effectiveness from clinical trials. Lower-risk or substantially-equivalent devices may instead use 510(k) clearance (equivalence to a legally marketed predicate) or the De Novo route (novel low-to-moderate-risk devices with no predicate). In the EU, the Medical Device Regulation assigns a risk class and requires conformity assessment and CE marking, typically via a notified body for high-risk implants.

Pathway choice shapes cost, evidence burden, and timeline: PMA demands pivotal-trial evidence and ongoing post-market obligations, whereas 510(k) and De Novo are lighter but unavailable to genuinely novel high-risk implants. Approval is always device- and indication-specific, and post-market surveillance requirements continue after launch rather than ending at approval.